|1.||Porubsky, Stefan: 2 articles (10/2014 - 09/2012)|
|2.||Gröne, Hermann-Josef: 2 articles (10/2014 - 09/2012)|
|3.||Jennemann, Richard: 2 articles (10/2014 - 09/2012)|
|4.||Porubsky, S: 1 article (11/2014)|
|5.||Lehmann, Lorenz: 1 article (10/2014)|
|6.||Salio, Mariolina: 1 article (09/2012)|
|7.||Singh, Yogesh: 1 article (09/2012)|
|8.||Müthing, Johannes: 1 article (09/2012)|
|9.||Bonrouhi, Mahnaz: 1 article (09/2012)|
|10.||Speak, Anneliese O: 1 article (09/2012)|
10/01/1984 - "From these results, lactoneotetraosylceramide and GM2 are possible candidates as cancer markers, because they seemed to be derived from cancer tissues by shedding."
03/15/1988 - "Detection of patients with cancer by monoclonal antibody directed to lactoneotetraosylceramide (paragloboside)."
10/01/1985 - "Immunological analysis of glycolipids on cell surfaces of cultured human tumor cell lines: expression of lactoneotetraosylceramide on tumor cell surfaces."
10/01/1985 - "Glycolipids of human cell lines of colonic adenocarcinoma (Colo 205 and BM 314), gastric tumor (AZ 521 and KATO-III), and lung tumor (A 549) were studied by the immunohistochemical fluorescence technique, flow cytometric analysis and immunostaining on thin layer chromatoplates with antibodies against gangliotriaosylceramide (Gg3Cer), gangliotetraosylceramide (Gg4Cer), fucogangliotetraosylceramide (Fuc-Gg4Cer), blood group B active lipid, globopentaosylceramide (Gb5Cer) and lactoneotetraosylceramide (nLc4Cer). "
|2.||Fabry Disease (Fabry's Disease)
11/01/2014 - "This implicates that substrate reduction therapy through inhibition of globosides might represent a new therapeutic option for Fabry disease, all the more so as globosides seem to be dispensable."
11/01/2014 - "The results on transgenic mice showed that in vital organs, such as the heart, kidneys and liver, it was possible to revert the phenotype of Fabry disease by eliminating the synthesis of globosides. "
10/01/2014 - "We conclude that substrate reduction therapy through inhibition of the synthesis of globosides and isoglobosides represents a valuable therapeutic option for Fabry disease, all the more as globosides and isoglobosides seem to be dispensable. "
10/01/2014 - "Depletion of globosides and isoglobosides fully reverts the morphologic phenotype of Fabry disease."
11/01/2014 - "Furthermore, globosides play a decisive role in the pathogenesis of Fabry disease which results from a decreased or absent activity of the lysosomal enzyme α-galactosidase A. "
|3.||Acute Kidney Injury (Acute Renal Failure)
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
|5.||Chronic Kidney Failure (Chronic Renal Failure)
|3.||Forssman glycolipid (GL-5)
|4.||Shiga Toxin (Shigella Toxin)